Among the various management options developed for neurodegenerative conditions, exogenous administration of NGF has become the prominent choice for AD (Jönhagen et al., 1998), PD (Olson et al., 1991; 1992; Jönhagen et al., 1998), and traumatic brain injury (Holtzman et al., 1996). Here, NGF is linked to Alzheimer disease.